Alpha 2.0
Login Register
» Articles » PMID: 35482574

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022

Overview
Journal MMWR Morb Mortal Wkly Rep
Date 2022 Apr 28
PMID 35482574
Authors
Kristie E N Clarke
Jefferson M Jones
Yangyang Deng
Elise Nycz
Adam Lee
Ronaldo Iachan
Adi V Gundlapalli
Aron J Hall
Adam MacNeil
Affiliations
Soon will be listed here.
Abstract

In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group.

Citing Articles

The Second Round of a Population-Based Seroprevalence Study of Anti-SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina.

Acimovic J, Mijovic B, Masic S, Petkovic M, Sladoje D, Knezevic D Influenza Other Respir Viruses. 2025; 19(1):e70053.

PMID: 39823154 PMC: 11739130. DOI: 10.1111/irv.70053.

Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021-February 2022.

Deng Y, Kim Y, Bratcher A, Jones J, Simuzingili M, Gundlapalli A Open Forum Infect Dis. 2025; 12(1):ofae719.

PMID: 39822271 PMC: 11736415. DOI: 10.1093/ofid/ofae719.

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence and Associated Risk Factors in a Large Cohort of US Children.

Katic B, Katragkou A, Alvitres J, Gurumurthy M, Li C, Schwab J Open Forum Infect Dis. 2025; 12(1):ofae680.

PMID: 39802208 PMC: 11718515. DOI: 10.1093/ofid/ofae680.

Covid-19, Diagnostic History and Mortality from Medicare 1999-2021, In an All-Cause Mortality Approach.

Williams N Arch Intern Med Res. 2024; 6(4):74-85.

PMID: 39726831 PMC: 11671151. DOI: 10.26502/aimr.0151.

Development and validation of the Post-COVID Symptom Scale for Children/Youth (PCSS-C/Y).

Tso W, Wang Y, Fong D, Kwan M, Ip P, Chan J Eur J Pediatr. 2024; 184(1):81.

PMID: 39673005 PMC: 11645425. DOI: 10.1007/s00431-024-05913-9.

References
1.
Lu P, Kong D, Shelley M . Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic. J Aging Health. 2021; 33(7-8):577-584. DOI: 10.1177/08982643211002084. View
2.
Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View
3.
Plumb I, Feldstein L, Barkley E, Posner A, Bregman H, Briggs Hagen M . Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(15):549-555. PMC: 9020856. DOI: 10.15585/mmwr.mm7115e2. View
4.
Shi D, Whitaker M, Marks K, Anglin O, Milucky J, Patel K . Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(16):574-581. PMC: 9042359. DOI: 10.15585/mmwr.mm7116e1. View